AI assistant
Sending…
BioLineRx Ltd. — Report Publication Announcement 2012
Feb 6, 2012
6692_rns_2012-02-06_cf993fa8-f171-4bf7-8bdb-ada16e13d38c.htm
Report Publication Announcement
Open in viewerOpens in your device viewer
_________ false
C002������� �� ��� ��"�2PublicBIOLINE RX LTD8688Corporation no: 513398750Stock Exchange/Market: ������� �� ���2271380����� 19 , ������� 91450 , ,Tel: 02-5489100 , 02-5489116 Fax: 02-5489101E.mail address: [email protected] of transmission: 06/02/2012 Time of broadcast: 13:54 13:53:46
Reference: 2012-02-034749
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on BioLineRx In-Licenses Second Oral Hepatitis C Treatment |
| 6K_06-Feb-2012_isa.pdf |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous names of reporting entity: |
| Date of revision of form structure: 31/01/2012 |
| - - - |
| Name of the Signatory: : Serlin Philip Adam , Position of Signatory in the reporting corporation: Chief Financial Officer , Name of Employer Company: . |
| Hartum St Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: [email protected] 2 |
More from BioLineRx Ltd.
Report Publication Announcement
2026
May 24
Regulatory Filings
2026
May 24
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 19
Report Publication Announcement
2026
May 19
Regulatory Filings
2026
May 19
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 28
Report Publication Announcement
2026
Apr 28
Regulatory Filings
2026
Mar 29